Founded in 2008, MyndTec is focused on commercializing innovative medical technologies through the company's extensive business, innovation and intellectual property expertise and through its work with leading global partners. MyndTec has developed rehabilitative therapies for upper body paralysis in stroke and spinal cord injury (SCI) patients and has received regulatory clearance for its MyndMove™ and MyndStep™ products in the U.S. and Canada. Working to overcome the challenges faced by early stage medtech companies, MyndTec has identified market needs and opportunities for new and innovative medical therapies, which it seeks to build upon through acquisition, licensing, research and development, and intellectual property expansion.
In 2022, MyndTec listed its common shares on the Canadian Securities Exchange (CSE) to allow the company the opportunity to attract additional investors, scale its business, and identify synergistic opportunities in delivering innovative medical technologies. The company's common shares are listed under the ticker MYTC on the CSE.
Our mission is to acquire, develop and build leading medical technologies that improve outcomes for patients, increase care team satisfaction and lower costs for providers.
Advancing the possibilities with bioelectronics
- Non-invasive neuro and nervous system electrical stimulation therapeutic device
- Treating upper body paralysis from neurological diseases and injury
- Non-invasive lower body FES therapeutic device
- Restore ankle dorsiflexion in foot drop patients after stroke, spinal cord injury, traumatic brain injury, multiple sclerosis and cerebral palsy patients